Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadAntiretroviral pharmacology in mucosal tissuesAssessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsPopulation pharmacokinetics of cefepime in the neonate.Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.Antibiotics and bacterial resistance in the 21st century.Staphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocolsCompartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilmsMultidrug therapy and evolution of antibiotic resistance: when order mattersExtended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Wise use of perioperative antibiotics.Pharmacokinetic analysis of oral doxycycline in rhesus macaques.The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuisAntimicrobial resistance in Haemophilus influenzaePopulation pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines.Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.Bacteraemic pneumococcal pneumonia: current therapeutic options.Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial.Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.Predicting the clinical efficacy of generic formulations of ceftriaxone.Efficacy of gamithromycin against Ornithobacterium rhinotracheale in turkey poults pre-infected with avian metapneumovirus.Pharmacokinetic and pharmacodynamic properties of gamithromycin in turkey poults with respect to Ornithobacterium rhinotracheale.Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulationsPulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae.Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Fluoroquinolone-resistant Streptococcus pneumoniae.LC-MS/MS determination of colistin in Mueller-Hinton broth for in vitro pharmacodynamic studies.Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs.The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.
P2860
Q22241905-B9ACFB76-FB93-456E-8CDB-AD5AFB1B33BFQ26822988-2A535C07-04EA-4146-B359-152252091526Q27014675-B66C1C44-61A8-498D-893A-58389AC2B8AFQ33552161-F4F5F79E-18E4-424E-9360-36EAF483A33BQ33883677-E21E22CF-F957-4A82-BFDB-689F669F4626Q34045319-BCDD86C5-9E1D-411F-BB9D-9A81017F2765Q34156349-0EE4CFBA-88E3-4483-97AA-5219A8FADC93Q34387384-8FA6E6D0-286F-403F-B1FA-C1B3D6CB2C99Q35091593-2B29E3C4-6CB1-4367-884D-121FABE89EE4Q36018792-B0B61854-4907-4353-98ED-8DEFBEBC1F60Q36156421-0DCEF1F6-3BE6-4E97-882C-B8993C9D43DCQ36162353-121D314A-6D03-4356-9260-603189A8887FQ36162355-C3E9A44D-5BBE-4F53-85C8-FE855C18ED5EQ36209344-A6EF2558-6E66-4D03-84EA-239B93FE61E9Q36673443-A9E5FBB6-BDAE-4AFC-82FF-DCE8C496AA93Q36713673-D4B0E184-6876-4212-9333-6D8DBF882B4EQ36788831-ACA0756A-5242-4B63-8E84-6CBE97FCD93BQ37298388-00E6F212-FF06-4466-8B0F-432AB860F79AQ37443615-B5A480E6-04CE-4A10-9168-B5D3B5EA0300Q37643682-1132483E-CB2B-431D-B837-62B3B2E9C84DQ37833059-50CD859E-CD3D-450F-A026-4E70B778EC2CQ38434088-A43A7274-66FC-472C-B7A3-91D2A2A83489Q39766949-651E94B8-8AF5-4069-B65F-6F14767F91A7Q40369183-C1D6D5A8-8ACF-4F95-A224-5712E9921EB3Q40677514-23AF6634-C1A2-4DB4-9185-F9A2C9C9FF07Q41098362-960AC236-4EE4-4624-B4C9-1FA444F560EDQ42006135-65989F5F-5716-4453-BAE3-99A74FA2EB58Q42031780-3785CA73-8BC1-4457-88C2-B92AAE290417Q42040822-F899DF81-C5E0-4880-B294-BC742A03C551Q42127654-C6CFFB40-08D5-477C-8E5F-41A94CA4F5D7Q42599563-F782FCD2-14CF-4972-981A-4B1C4476CFD1Q45281920-D035B461-2981-48BA-A3A0-5A4239076E1DQ46143642-A4F1C031-70C3-43A3-935B-8A0BC8F1D0D4Q47701094-AA6FFADC-BA97-4598-8788-2C4A3CEE8CD2Q49210057-418EBBE2-0265-4DE8-80DC-A8240D6B9713
P2860
Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Application of pharmacokinetic ...... respiratory tract infections.
@ast
Application of pharmacokinetic ...... respiratory tract infections.
@en
type
label
Application of pharmacokinetic ...... respiratory tract infections.
@ast
Application of pharmacokinetic ...... respiratory tract infections.
@en
prefLabel
Application of pharmacokinetic ...... respiratory tract infections.
@ast
Application of pharmacokinetic ...... respiratory tract infections.
@en
P2093
P1476
Application of pharmacokinetic ...... f respiratory tract infections
@en
P2093
Michael R Jacobs
William A Craig
P304
P356
10.1016/J.CLL.2004.03.009
P50
P577
2004-06-01T00:00:00Z